E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Opioid Induced Constipation |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10010774 |
E.1.2 | Term | Constipation |
E.1.2 | System Organ Class | 10017947 - Gastrointestinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of methylnaltrexone in producing laxation in patients sedated with opioid infusions. |
|
E.2.2 | Secondary objectives of the trial |
1. To assess if the use of methylnaltrexone leads to increased opioid requirements through CNS penetration and antagonism
2. To assess if there are additional benefits from preventing constipation such as reduced gastric stasis, improved enteral feeding, and a reduction in infection
3. To assess the safety and side effect profile of intravenous methylnaltrexone in ICU patients
4. Blood will further analysed and stored for: • Cytokine levels • Leucocyte function assays • Metabolic profiles |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Males and females ≥ 18 years of age • Following ICU admission, sedated with opioids and requiring invasive ventilator support • Scheduled for continuous infusion/administration of opioid analgesics for at least a further 24 hours • Constipated (not opened bowels for a minimum 48 hours following ICU admission) • Access for enteral administration of medications and nasal-gastric tube feeds • Initiation of nasogastric tube feeds • Patient weight of 38-114kg (this allows pre preparation of drug with either 8mg or 12mg) |
|
E.4 | Principal exclusion criteria |
• Known to be pregnant • Patients with end stage renal failure requiring dialysis on admission • Diarrhoea on admission • Abdominal surgery within 8 weeks prior to ICU admission • Presence of Ileostomy or colostomy • Mechanical gastrointestinal obstruction • Suspected Acute surgical abdomen • History of Crohn's disease or ulcerative colitis • On Palliative care or not expected to survive more than 12 hours • Severe chronic hepatic impairment (Child Pugh Class C) • Suspected hepatic encephalopathy • Known to have received another IMP within 30 days or currently in another interventional trial that might interact with the study drug or previously enrolled into MOTION
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to rescue-free opening bowels following randomisation. Significant bowel opening is defined as an estimate of stool volume of greater than 100nls by the attending nurse. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Up to 28 days after randomisation. |
|
E.5.2 | Secondary end point(s) |
• Gastric Residual Volume measured every 4 hours and totalled over 24 hours • Toleration of enteral feeds: Daily assessment of % of patients achieving full target enteral feeding • Requirement of rescue laxatives (1/2 sachet picolax, 2 glycerin suppositories) • Requirement of prokinetics (10mg metoclopramide tds, 250mg erythromycin qds) • Average number of bowel movements per day • Escalation of opioid dose due to antagonism/reversal of analgesia and sedation • Incidence of ventilator associated pneumonia (VAP), defined by the Clinical Pulmonary Infection Score (CPIS) • Incidence of diarrhoea • Incidence of Clostridium difficile infection: PCR or Toxin positive • Incidence of positive microbiology blood cultures • Mortality: 28 day, ICU and Hospital
Secondary mechanistic Outcomes: • Sepsis Biomarkers • Leucocyte Function Tests • Leucocyte Migration Assays |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Daily througout trial and up to 28 days after randomisation. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will end when the specified numbers of patients (84) have been recruited, the last patient has been discharged from hospital (or a maximum of 3 months from randomisation of the last patient), and the database is locked. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 1 |